Skip to main content
. 2019 Sep 24;14(9):e0222537. doi: 10.1371/journal.pone.0222537

Fig 2. Comparison of rejection-free survival.

Fig 2

(a) Biopsy-proven acute rejection free survival in HLAi, ABOi, HLAi+ABOi, control, and LD control groups. (b) Active antibody-mediated rejection free survival in HLAi, ABOi, HLAi+ABOi, control, and LD control groups. Abbreviations: ABOi, ABO-incompatible; ABMR, antibody-mediated rejection; BPAR, biopsy-proven acute rejection; HLAi, HLA-incompatible; LD, living-donor.